Bio Sequence

Ways to Evaluate the Worldwide R&D Progress of Our Study Sequence

13 September 2023
2 min read

You can utilize databases for querying and analysis, and I believe the Patsnap Bio Sequence Database can be helpful. First, apply for a free account registration. In the "Sequence Search" section on the left side, enter your sequence using formats such as uploaded sequence, Sequence Code, GenBank ID, or CAS RN. Then, on the right side, select the sequence type and use advanced settings to specify parameters such as sequence similarity and length for the BLAST search. Click on the search button to present all the available data related to your sequence, including patents, biological journals, literature, and public biological databases.

This extensive collection of relevant data allows you to filter and refine the results based on various sequence selection options to focus on the specific data of interest. You can download mutation reports, export FASTA files, view public sources, save sequences, and set email alerts. You can access detailed information about the sequence for further research and analysis by clicking on patents, literature, journals, or other databases.

图形用户界面, 应用程序, Teams

描述已自动生成

The Patsnap Bio Sequence Database offers comprehensive and convenient retrieval, allowing for fast searching and analysis of globally known similar sequences. It facilitates online sequence alignment and analysis, enabling you to understand risks and competitive intelligence better. Apply for an account and start exploring and sharing with your colleagues. 

Free registration is currently available to utilize the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
Latest Hotspot
3 min read
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
13 September 2023
Biotech firm, Phanes Therapeutics, has announced its Phase 1 clinical trial of PT217, a first-in-class drug targeting DLL3 and CD47 in small cell lung cancer. The trial uses a new IgG-like bispecific antibody and the first patient has been treated.
Read →
Searching for Modified Sequences: The Best Biological Databases to Consider
Bio Sequence
2 min read
Searching for Modified Sequences: The Best Biological Databases to Consider
13 September 2023
Sequence modification is an important attribute of a sequence, particularly in the field of small nucleic acids. Sequence modifications, including fluorescence labeling, glycosylation, phosphorylation, and others, can enhance the functionality of a sequence, making them highly meaningful. In the Patsnap Bio Sequence Database, you can search for modified sequences.
Read →
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
Latest Hotspot
4 min read
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
13 September 2023
Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.
Read →
JAK1 Inhibitor - A rising star of small molecule targeted drugs in the field of autoimmunity
JAK1 Inhibitor - A rising star of small molecule targeted drugs in the field of autoimmunity
13 September 2023
In autoimmune diseases, JAK inhibitors can mediate immune suppression and inhibit the increase of serum pro-inflammatory cytokines.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.